Amgen quarterly results beat Wall Street estimates

Amgen reported stronger-than-expected Q2 results, with revenue up 9% to $9.2 billion and adjusted EPS up 21% to $6.02, driven by robust product sales including a 31% increase for Repatha. Despite higher operating expenses due to R&D for its experimental weight-loss drug MariTide, the company slightly raised its full-year financial outlook. A significant catalyst for investors will be the anticipated release of mid-stage data for MariTide in Q4, positioning Amgen in the rapidly growing obesity treatment market.

Analysis

Amgen (AMGN) delivered a strong second-quarter performance, exceeding Wall Street expectations with revenue rising 9% to $9.2 billion and adjusted earnings per share increasing 21% to $6.02. This outperformance was driven by a 9% rise in product sales, highlighted by a significant 31% sales increase for its cholesterol medication Repatha to $696 million. However, this growth was partially offset by notable headwinds, including an 18% increase in R&D costs associated with its experimental weight-loss drug, MariTide, and a 4% sales decline for its bone drug Prolia, which faces further expected erosion from biosimilar competition. The company modestly raised its full-year guidance, a positive signal, but the primary focus for investors is now the forthcoming mid-stage data for MariTide, expected in the fourth quarter. This positions Amgen for a potential entry into the lucrative obesity market, making the Q4 data a pivotal catalyst for the stock's future trajectory. The muted after-hours stock movement suggests the market may be looking past the current strong results and adopting a 'wait-and-see' approach ahead of this key clinical readout, while also remaining cognizant of sector-wide risks like potential tariffs and drug pricing pressures.

Key Decisions for Investors

• The primary investment thesis for Amgen now hinges on the pivotal mid-stage data for its weight-loss drug MariTide, expected in Q4, which could significantly rerate the stock.
• Investors should closely monitor sales of the bone drug Prolia, as management's guidance for continued erosion from biosimilar competition represents a material headwind to the base business.
• Given the modest stock reaction to a strong earnings beat, consider that the market may be awaiting the MariTide catalyst, implying that positions should be managed for potential volatility around the Q4 data release.
• Factor in persistent sector-wide political and regulatory risk, as the company's outlook does not account for potential future tariffs or drug pricing reforms, which remain a key uncertainty.